Ovid Therapeutics to Present at Upcoming September Investor Conferences
September 04 2024 - 7:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company
dedicated to improving the lives of people affected by rare
epilepsies and brain conditions, today announced that management
will participate in two upcoming investor conferences in September:
- H.C. Wainwright 26th Annual
Global Investment Conference – Ovid will present on September 10th
at 3:30 p.m. ET.
- Cantor Global Healthcare
Conference – Ovid will participate in a fireside chat on Tuesday,
September 17th at 1:55 p.m. ET.
Live webcasts of the fireside chat and presentation can be
accessed through the Events & Presentations section of the
Company’s website at investors.ovidrx.com. An archived replay of
the webcast will be available on the Company’s website following
the live presentation.
About Ovid TherapeuticsOvid Therapeutics Inc.
is a New York-based biopharmaceutical company that is dedicated to
improving the lives of people affected by rare epilepsies and brain
conditions with seizure symptoms. The Company is advancing a
pipeline of novel, targeted small molecule candidates that modulate
the intrinsic and extrinsic factors involved in neuronal
hyperexcitability causative of seizures and other neurological
symptoms. Ovid is developing: OV888/GV101 capsule, a potent and
highly selective ROCK2 inhibitor, for the potential treatment of
cerebral cavernous malformations and other rare central nervous
system diseases; OV329, a GABA-aminotransferase inhibitor, a
potential therapy for treatment-resistant seizures; and OV350, a
direct activator of the KCC2 transporter, for the potential
treatment of epilepsies and other psychiatric conditions. For more
information about these and other Ovid research programs, please
visit www.ovidrx.com.
Investor Relations:Garret
Bonney617-735-6093gbonney@ovidrx.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Sep 2023 to Sep 2024